Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.2
Commitments and Contingencies (Details Narrative)
1 Months Ended 6 Months Ended
May 01, 2020
d / Tradingdays
$ / shares
Nov. 30, 2019
USD ($)
Nov. 30, 2017
USD ($)
Nov. 30, 2016
USD ($)
ft²
Jun. 30, 2020
USD ($)
May 14, 2020
$ / shares
Apr. 15, 2020
Dec. 31, 2019
Monthly lease payments         $ 112,846      
Alachua Facility [Member]                
Period of lease               5 years
Tampa Facility [Member]                
Period of lease   36 years   36 months        
Area of office space leased | ft²       2,207        
Lease expiry date       Feb. 29, 2020        
Minimum [Member] | Amended Lease Agreement [Member]                
Monthly lease payments         12,870      
Minimum [Member] | Tampa Facility [Member]                
Monthly lease payments   $ 4,524   $ 4,138        
Maximum [Member] | Tampa Facility [Member]                
Monthly lease payments   $ 4,800   $ 4,392        
Short Term Warrants [Member]                
Warrants exercise price per share | $ / shares           $ 0.75    
Trading days | d / Tradingdays 21              
Warrants maturity date             May 14, 2020  
Stock Purchase Agreement [Member] | Warrants [Member] | Noachis Terra Inc. [Member]                
Warrants exercise price per share | $ / shares $ 1.25              
Contingent consideration description (i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding.              
Percentage of warrant exercise 20.00%              
Stock Purchase Agreement [Member] | Warrant One [Member] | Noachis Terra Inc. [Member]                
Percentage of warrant exercise 45.00%              
Stock Purchase Agreement [Member] | Mr. Joseph Hernandez [Member] | Warrants [Member] | Minimum [Member]                
Warrants exercise price per share | $ / shares $ 0.75              
Stock Purchase Agreement [Member] | Mr. Joseph Hernandez [Member] | Warrants [Member] | Minimum [Member] | Noachis Terra Inc. [Member]                
Warrants exercise price per share | $ / shares 0.75              
Stock Purchase Agreement [Member] | Mr. Joseph Hernandez [Member] | Warrants [Member] | Maximum [Member]                
Warrants exercise price per share | $ / shares 0.90              
Stock Purchase Agreement [Member] | Mr. Joseph Hernandez [Member] | Warrants [Member] | Maximum [Member] | Noachis Terra Inc. [Member]                
Warrants exercise price per share | $ / shares 0.90              
Stock Purchase Agreement [Member] | Mr. Joseph Hernandez [Member] | Warrant One [Member]                
Warrants exercise price per share | $ / shares $ 1.00              
Percentage of warrant exercise 45.00%              
License Agreement [Member]                
Royalty expenses         30,000      
Reimbursement expenses         11,739      
Lantibiotic Exclusive Channel Collaboration [Member]                
Royalty rate percentage description     The Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company's election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program.          
Royalty payment of sublicenses percentage     25.00%          
Amount required to expended for advancement of lantibiotic program     $ 1,200,000          
Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member] | Amendment [Member]                
Royalty payment percentage     10.00%          
Lantibiotic Exclusive Channel Collaboration [Member] | Cost Of Revenue [Member]                
Royalty payment percentage     25.00%          
Lantibiotic Exclusive Channel Collaboration [Member] | Product Profit [Member]                
Reduction in royalty rate percentage     25.00%          
Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member]                
Reduction in royalty rate percentage     10.00%          
Lantibiotic Exclusive Channel Collaboration [Member] | New Drug Application [Member]                
Milestone payment under licensing agreement     $ 25,000,000          
Milestone measurement period     6 months          
Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]                
Milestone payment under licensing agreement     $ 25,000,000          
Milestone measurement period     6 months          
Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]                
Milestone payment under licensing agreement     $ 5,000,000          
Milestone measurement period     6 months          
Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]                
Milestone payment under licensing agreement     $ 5,000,000          
Milestone measurement period     6 months          
Amended Lease Agreement [Member] | Maximum [Member]                
Monthly lease payments         $ 13,338